Intended for US healthcare professionals only.
Menu
Visit Patient Site

Refer to the Introducing Optune Dialogue Tool to help you answer questions and get patients started on Optune.

4 steps to help you integrate Optune into your practice

Click on these 4 steps to help you integrate Optune into your practice

1

DISCUSS treatment plan with multidisciplinary team, patient, and caregiver

A coordinated approach with your multidisciplinary team is key for ensuring consistent communication with patients and caregivers

Present Optune in a way that addresses your patient’s needs and concerns

Remind patients and caregivers about the support available to them through nCompass®

Recommend the Buddy Program. It allows your patients to speak with current Optune users who can share their personal experiences using Optune. Go to Optune Buddy Program Enrollment

Reinforce the treatment plan at subsequent visits

Introducing Optune Dialogue Tool

Find patient-friendly language to assist you in discussing Optune with patients and caregivers.

View this PDF
2

SUBMIT prescription order form and supporting documentation

Submit: Office submits complete prescription order.

nCompass will begin the benefits investigation on behalf of your patient. After submission, your assistance may be needed. If so, you will be contacted by an nCompass team member.

Support: Once the prescription is processed, the Optune Treatment Kit is delivered to your patient’s designated Device Support Specialist (DSS).

Initiate: DSS delivers the Optune Treatment Kit to your patient and completes technical training in the home (or clinic).

nCompass Brochure

See the nCompass brochure for more information and patient support to learn how nCompass supports patients at every step of their journey.

View this PDF
3

FOLLOW UP 2 weeks post Optune initiation to review integration and skin care

Schedule a follow-up with your patient 2 weeks after initiation to encourage a positive response.

Discuss integrating Optune into daily life and proper skin care, as managing skin-related AEs is paramount to optimizing time on therapy.

Management Guidelines for Dermatologic Adverse Events (dAEs) Brochure

This brochure provides guidance to you and your practice for identifying, preventing, and managing dAEs for Optune users.

View this PDF
4

MANAGE each patient via monthly follow-ups and review of the Optune Usage Report

Maintaining treatment with Optune is critical for the realization of maximal treatment benefit

Review the monthly Optune Usage Report to help

  • Gain insights into how well each patient is adjusting to treatment with Optune
  • Establish usage goals that are appropriate for each patient

Each patient can also contact their Device Support Specialist (DSS) for tips to help optimize their time on Optune.

Monthly Usage Fact Sheet

Learn how a greater survival benefit was achieved with increased Optune use.

View this PDF

MyLink™ makes usage data collection easier

MyLink lets your patients easily upload their Optune device data to the remote storage server from the comfort of their homes

Increases Novocure’s virtual patient support capability and enables your Novocure DSS to better support your patients

Provides you the usage information you need to monitor their treatment

MyLink Quick Reference Card

Introduces patients to the MyLink hardware and provides a step-by-step guide of how to use it.

View this PDF

Managing GBM remotely? Optune continues to be a viable treatment choice

These telemedicine best practices have been developed to address the evolving nature of patient care.

1. Scheduling

  • Have a dedicated staff for scheduling
  • Obtain verbal consent from patients
  • Remind patients that the appointment start time may vary

2. Preparation

  • Dial in to the virtual platform early to address potential technical issues
  • Pull up all files to be shared in advance

3. Conducting

  • Have participants introduce themselves (can include caregiver)
  • Speak slowly, clearly, and concisely
  • Encourage patients and/or caregivers to take notes
  • Leave time for patients and caregivers to ask questions

4. Concluding

  • Have the patient and/or caregiver read back the counsel provided
  • Determine if telemedicine is right for the individual patient

nCompass Brochure

See the nCompass brochure for more information and patient support to learn how nCompass supports patients at every step of their journey.

View this PDF

Contact nCompass for all support needs

Call us any time of day:

1-855-281-9301 (toll-free)

Or email us:

support@novocure.com

Watch Dr. Khagi’s video as he shaves his head in solidarity with his patients and sees first hand what wearing Optune is like

Learn more below

Patient support

Indications for Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

If the patient has an underlying serious skin condition on the scalp (e.g. ulcers, open wound, broken skin) evaluate whether this may prevent or temporarily interfere with Optune treatment.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings and precautions.

Read more

Indications for Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

If the patient has an underlying serious skin condition on the scalp (e.g. ulcers, open wound, broken skin) evaluate whether this may prevent or temporarily interfere with Optune treatment.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings and precautions.

Leaving Optune.com

Novocure does not review the information contained on this website and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the website and/or database producer.

Novocure makes no representation as to the accuracy or any other aspect of the information contained on such website and/or database, nor does Novocure necessarily endorse such website and/or database.

OK

Sie verlassen nun die Website welche nur für Verbraucher/Patienten der USA vorgesehen ist. Die Website welche Sie nun öffnen richtet sich ausschließlich an in Deutschland ansässige Verbraucher/Patienten.

Bitte klicken Sie auf “Ok” um zu bestätigen dass Sie verstehen, dass sich diese Internet-Seite ausschließlich an Verbraucher/Patienten in Deutschland richtet.

You are currently leaving Optune.com. The site you are about to visit is intended for German users/patients only.

OK

現在アメリカ国内向けの専用のサイトから日本の医療従事者向けの専用サイトへ移動しようとしています。

よろしければ ”OK” をクリックすることで日本の医療従事者向け専用のサイトへ移動します。

You are currently leaving Optune.com. The site you are about to visit is intended for Japanese residents only.

OK